Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jessica J. Lin"'
Autor:
David R. Gandara, Thomas E. Stinchcombe, Caroline E. McCoach, Alison M. Schram, Emilio Paul Araujo-Mino, Timmy Nguyen, Jorge Nieva, Aditya Bardia, Lesli A. Kiedrowski, Alessandro Russo, Janakiraman Subramanian, David S. Hong, Christian Rolfo, Kristin Price, Alexander Drilon, Afshin Dowlati, Jessica J. Lin, Stephen V. Liu, Michael A. Morse, Deepa Sashital, Mohammad Mobayed, Neelima Vidula, Shahrooz Eshaghian, Scott N. Gettinger, Sarah B. Goldberg
Publikováno v:
Br J Cancer
Background Activating fusions of the NTRK1, NTRK2 and NTRK3 genes are drivers of carcinogenesis and proliferation across a broad range of tumour types in both adult and paediatric patients. Recently, the FDA granted tumour-agnostic approvals of TRK i
Autor:
Islam Baiev, Jochen K. Lennerz, Lesli A. Kiedrowski, Mohammed Usman Syed, Chendi Li, Rebecca S. Heist, Samuel J. Klempner, Dejan Juric, Aaron N. Hata, Mustafa Sakhi, Katerina A. Fella, Ryan B. Corcoran, Alexa G. Michel, Justin F. Gainor, Junbing Zhang, Liron Bar-Peled, Jessica J. Lin, Meagan B. Ryan, Noritaka Tanaka, Giulia Siravegna
Publikováno v:
Cancer Discovery. 11:1913-1922
Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have demonstrated efficacy in KRASG12C-mutant cancers, including non–small cell lung cancer (NSCLC). However, mechanisms underlying clinical acquired resista
Autor:
George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 7
Purpose: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in adults with NTRK fusi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aa47e6bf8e1aa14128497f92320a8fb
https://escholarship.org/uc/item/62k9z94t
https://escholarship.org/uc/item/62k9z94t
Autor:
Geoffrey R. Oxnard, Satoshi Yoda, Bruce G. Robinson, Eliana B. Gomez, Sarah-Jane Dawson, S. Michael Rothenberg, Justin F. Gainor, Dahlia Henry, Oliver Gautschi, Christine Khoo, Stephen Q. Wong, Edward Y. Zhu, Andrew T. Metcalf, Louis Stancato, Brian B. Tuch, Barbara J. Brandhuber, Steve Andrews, Jessica J. Lin, Lavinia Tan, Kevin Ronald Condroski, Vivek Subbiah, Lecia V. Sequist, Wayne Blosser, James F. Blake, Joshua Ballard, Kolakowski Gabrielle R, Kevin Ebata, Alexander Drilon, Benjamin Solomon, Michele Nguyen, Sebastian Hollizeck
Publikováno v:
Journal of Thoracic Oncology. 15:541-549
Introduction Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and R
Autor:
Victor Vaz, John V. Heymach, Natalie I. Vokes, Liam F. Spurr, Jacklynn V. Egger, Biagio Ricciuti, Subba R. Digumarthy, Andrew D. Cherniack, Ferdinandos Skoulidis, Andrew J. Plodkowski, Michael Y. Tolstorukov, Xinan Wang, Jessica J. Lin, Nuno Vaz, Jianjun Zhang, Gonzalo Recondo, Deepti Venkatraman, Justin F. Gainor, David A. Barbie, Giuseppe Lamberti, Mehmet Altan, Yvonne Y. Li, Lingzhi Hong, Lynette M. Sholl, Hye Sun Park, Kathryn C. Arbour, Matthew D. Hellmann, Mark M. Awad, Mizuki Nishino, Amir Vajdi, Joao Victor Machado Alessi, Hira Rizvi, Sara Khosrowjerdi
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 17(3)
Introduction STK11 and KEAP1 mutations (STK11 mutant [STK11MUT] and KEAP1MUT) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11MUT has been associated with resistance to programmed death-(ligand)1 (PD-[L]1) inhibiti
Autor:
Jessica J. Lin, Yunan Nie, Alexia Iasonos, Andrew J. Plodkowski, Maria E. Arcila, Debra A. Goldman, Jaime L. Schneider, Viola W. Zhu, Sai-Hong Ignatius Ou, Natasha Rekhtman, Alexander Drilon, Subba R. Digumarthy, Tejas Patil, Jamie E. Chaft, Christina Falcon, Andrew Do, Noura J. Choudhury, Soo-Ryum Yang
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100187-(2021)
Introduction: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype ha
Autor:
Catherine M. Albert, Francois P. Doz, Shivaani Kummar, D.S.W. Tan, Theodore W. Laetsch, Hendrik Nogai, Raymond S. McDermott, C.M. van Tilburg, A. Drilon, Stefan S. Bielack, Jordan Berlin, Jessica J. Lin, Makoto Tahara, Ulrik Lassen, David S. Hong, Ricarda Norenberg, R. Xu, Liang Shen, Marc Mardoche Fellous
Publikováno v:
Annals of Oncology. 32:S599-S600
Autor:
Alice T. Shaw, Jochen K. Lennerz, Mari Mino-Kenudson, Hideko Isozaki, Subba R. Digumarthy, Inga T. Lennes, Rebecca J. Nagy, Corinne Clifford, Aaron N. Hata, Jessica J. Lin, Lecia V. Sequist, Mandeep Banwait, Amanda K. Riley, Dora Dias-Santagata, Justin F. Gainor, Zofia Piotrowska, Sai-Hong Ignatius Ou, Varuna Nangia, Viola W. Zhu, Rebecca S. Heist, Richard B. Lanman, Nicolas Marcoux, Wenjia Su, A. John Iafrate, Satoshi Yoda, Erica Evans, Beni B. Wolf
Publikováno v:
Cancer Discovery. 8:1529-1539
We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired CCDC6–RET fusion. Although RET fusions have been identified in resistant EGFR-mutant non–small cell lung cancer (NSCLC), their role in acquired
Autor:
Kimmie Ng, Aaron R. Thorner, George D. Demetri, Lauren K. Brais, Emma Reilly, Jeffrey A. Meyerhardt, Atul B. Shinagare, Cheta Siletti, Geoffrey I. Shapiro, Jason L. Hornick, Jessica J. Lin, Matthew D. Ducar, Anna F. Farago, Ewa Sicinska, Liam F. Spurr, Andrew D. Cherniack, Laura E. MacConaill, Rachel B. Keller, Brian M. Wolpin, Azra H. Ligon, Rahul Gujrathi, Matthew Meyerson, Marios Giannakis, Ritika Abhyankar, James M. Cleary, Jeffrey W. Clark, Harshabad Singh, Anwesha Nag, Yvonne Y. Li, Matthew H. Kulke
Publikováno v:
Clin Cancer Res
Purpose: Receptor tyrosine kinase fusions in colorectal cancers are rare, but potentially therapeutically relevant. We describe clinical, molecular, and pathologic attributes of RTK fusion–associated colorectal cancer. Experimental Design: We ident
Autor:
Laura A. Petrillo, Haiwen Gui, Ashley Zhou, Jennifer S. Temel, Jessica J. Lin, Robert K. Sommer, Lara Traeger, Joseph A. Greer, Ryan D. Nipp
Publikováno v:
Journal of Clinical Oncology. 39:161-161
161 Background: Patients and caregivers seek information about cancer from a variety of sources in addition to their medical team. In recent years, patients with specific lung cancer subtypes have created advocacy groups with active online forums for